2Zhu Y,ShennanM,Reynolds KK,et al.Estimation of warfarin maintenance dose based on VKORC1 (21639G》A) and CYP2C9 genotypes.Clin Chem,2007;53(7):1199.
3LimdiNA,McGwin C,Goldstein JA,et al.Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic computations in African-American and European-American patients onl warfarin.Clin Pharmacol Ther,2008;83(2):312.
4SeordoMG,Pengo V,Spins E,et al.Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.Clin Pharmacol Ther,2002;72(6):702.
5Rost S,Fregin A,Ivaskevieius V,et al.Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2.Nature,2004;427(6974):537.
6RiederMJ,RienerAP,Gage BF,et al.Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose.N EngI J Med,2005;352 (22):2285.
7Voora D,Meleod H L,Eby C,et al.Use of phamacogenetics to guide warfarin therapy.Drugs Today,2004;40(3):247-257.
10Horst kotte D,Schulte H,Bircks W,et al.Unexpected findings concerning thromboembolic complications and anticoaguhtion after complete 10 year follow up of patients with St.Jude medical prost hesis.Heart valve dis,1993;2(3):291-301.
7Hirsh J,Dalen J,Guyatt G. The sixth(2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians [J]. Am Coll Chest Physic, 2001,119(1 Suppl), 1-2.
8Weinstock DM, Chang P, Aronson DL, et al. Comparison of plasma prothrombin and factor Ⅶ and urine prothrombin F1 concentrations in patients on long-term warfarin therapy and those in the initial phase[J].Am J Hematol,1998,57(3):193-199.
9Soga Y,Okabayashi H,Nishina T,et aL Lip to 8-year followup of valve replacement with carbomedics valve [J]. Ann Thorac Surg, 2002,73(2) :474-479.
10Acar J, lung B, Boissel JP, et al. AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation, 1996,94:2107-2112.
6Miao LY,Yang J,Huang CR,et al.Contribution of age,body weight,and CYP2C9and VKORC1genotype to the anticoagulant response to warfarin:proposal for a new dosing regimen in Chinese patients[J].Eur J Clin Pharmacol,2007,63(12):1135-1141.
7Yin T,Miyata T.Warfarin dose and the pharmacogenomics of CYP2C9and VKORC1-Rationale and perspectives[J].Thrombosis Research,2007,120(1):1-10.
